The University of Pennsylvania and Agios Pharmaceuticals on Friday announced a licensing agreement to develop products that can diagnose cancer by detecting the metabolism of cancer cells.
The agreement resolves two lawsuits that Penn, its trustees, and its Abramson Family Cancer Research Institute brought in December against Craig B. Thompson, a cancer metabolism researcher who left Penn in 2011 to head Memorial Sloan-Kettering Cancer Center.
Thompson held key positions at Penn, including director of the Abramson Cancer Center. He cofounded Agios in 2007 in Cambridge, Mass. The lawsuits, which also named Agios, accused him of stealing intellectual property developed at Penn.
